Company news

OSE Immunotherapeutics SA news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

OSE Immunotherapeutics lance une Newsletter pour les investisseurs individuels

July 17, 2025

OSE Immunotherapeutics met à jour l’information sur les procédures en cours

July 2, 2025

OSE Immunotherapeutics Publishes Letter to Shareholders

June 30, 2025

OSE Immunotherapeutics provides an update on ongoing proceedings

June 25, 2025

OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market Rules

June 20, 2025

Adjournment of the general meeting initally convened on June 25, 2025

June 11, 2025

Update on the terms of the shareholders general meeting

June 9, 2025

OSE Immunotherapeutics strengthens Growth Strategy: Accelerates key pillars of Inflammation and Immuno-Oncology

June 4, 2025

Documents made available to the shareholders for the combined general meeting of June 25th, 2025

June 4, 2025

OSE Immunotherapeutics Provides Clinical Updates on Neo-Epitope Based Cancer Vaccine Tedopi® in Pancreatic Cancer and Non-Small Cell Lung Cancer

June 2, 2025

OSE Immunotherapeutics Announces that its Partner Boehringer Ingelheim Will Present Early Clinical Evidence of Innate Immune Modulation and Anti-Tumor Activity via SIRPα Blockade in Two Ongoing Trials at ASCO 2025

May 23, 2025

OSE Immunotherapeutics Announces Strategic Collaboration to Pioneer Novel mRNA Technologies

May 21, 2025

OSE Immunotherapeutics Announces >90% of Responders Maintained Symptomatic Remission Through Extension Period on Lusvertikimab

May 5, 2025

← Newer news releases

Decks

The 5 newest of 26 decks. Every deck is listed under its year.